Magnetic sorting and genomic technique for drug discovery – The Engineer
Posted: September 25, 2019 at 8:44 am
Canadian researchers bring together microfluidic and genomic technologies for drug discovery in cancer and regenerative medicine
The project, which also involved electrical engineers, is aimed at searching the human genome for genes, and the associated protein products, that can be targeted by drugs to treat a variety of illnesses. This is normally a very lengthy task, but research leaders Shana Kelley and Jason Moffat of the University of Toronto reasoned that combining the techniques they were working on respectively, a magnetic sorting technique and gene-editing using CRISPR might speed the process up. As they report in a paper in Nature Biomedical Engineering, their hunch was correct.
Both researchers were working on a large multi-centre project called Medicine by Design, with Kelley, a pharmacist, leading a team that was building microfluidic devices which use tiny magnets incorporated into cells to sort large mixed populations of cells. Moffat, a cellular and biomedical research specialist, was using CRISPR, a powerful technique for identifying and manipulating specific genes in cells, to study how the bodys immune system is triggered to attack certain cells but not others. A conversation in a corridor led researchers to combine their research strands, resulting in what Kelley calls an engine for the discovery of new therapeutic targets in cells.
_______________________________________________________
_______________________________________________________
The teams paper describes how they used CRISPR to reveal promising drug targets by switching off genes that produce proteins that help cancer to spread. Using techniques developed by Kelley, the researchers bound tiny magnetic particles to the target proteins which reside on the surface of the cells that produce them, and funnelled the entire population of cells into a device about half the size of a credit card, streaked with strips of magnetic material that capture the marked cells into collection channels corresponding to the amount of magnetic material on the surface, which corresponded to the concentration of the target protein.
To test the method, they focused on cancer immunotherapy, a technique which tricks the immune system into attacking mutated cancer cells (normally, these would be ignored, leading to growth and spread of the cancer). Using CRISPR, they identified a gene that produces a protein known as CD47, which signals immune cells not to attack cancer cells often hijack this process to escape detection. Previous research had indicated that blocking CD47 directly with drugs leads to harmful side effects, so just tricking the cell to produce less might be a more effective treatment. The CRISPR screen identified an enzyme that helps camouflage the protein from the immune system, and could be blocked with an off-the-shelf drug, and the microfluidic device successfully sorted cells with the gene producing the enzyme from a mixed population of cells.
As many as one billion cells can travel down this highway of magnetic guides at once and we can process that in one hour, says Kelley. Its a huge gamechanger for CRISPR screens. Using current sorting techniques, which employ fluorescent markers picked out by lasers, the same sorting procedure would take 20-30 hours, making drug discovery an expensive and arduous task.
Kelley and Moffat also hope the technique can be used in regenerative medicine, to identify genes that activate stem cells to transform into specific cell types, which would make it easier to harvest the right sort of cells for therapies.
More:
Magnetic sorting and genomic technique for drug discovery - The Engineer
- Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ? - Yahoo Finance - December 12th, 2019
- Science Fiction Becoming Reality - Reporter Magazine - December 12th, 2019
- Viewpoint: Conservatives say UK could break from 'outdated' EU GMO, CRISPR regulations if they sweep 'Brexit election' - Genetic Literacy Project - December 12th, 2019
- CRISPR Technology Market: 2020 With Top Competitors Analysis And Insights - Sound On Sound Fest - December 12th, 2019
- Gene therapy could be a revolutionary new treatment for sickle cell disease - The Hill - December 12th, 2019
- GenEdit and Editas Medicine Enter into Exclusive License and Collaboration Agreement for Nanoparticle Gene Therapy Delivery - Business Wire - December 12th, 2019
- A year after the first CRISPR babies, stricter regulations are now in place - The Conversation CA - December 11th, 2019
- ERC promotes CRISPR research to better treat infections - News-Medical.net - December 11th, 2019
- Global CRISPR Genome Editing Market 2019 by Company, Regions, Type and Application, Forecast to 2025 - The Market-News 24 - December 11th, 2019
- New Viral Strategy to Escape Detection Discovered by Researchers - SciTechDaily - December 11th, 2019
- Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR) Technology Market with Future Prospects, Key Player SWOT Analysis and Forecast To... - December 11th, 2019
- New Details About The Infamous 'CRISPR Babies' Experiment Have Just Been Revealed - ScienceAlert - December 9th, 2019
- Gene editing will let us control our very evolution. Will we use it wisely? - The Guardian - December 9th, 2019
- Five technologies that may alter India in 2020 - Livemint - December 9th, 2019
- Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable - The Motley Fool - December 9th, 2019
- Hopkins team invents non-viral system for getting gene therapy into cells - FierceBiotech - December 9th, 2019
- 2019: The year gene therapy came of age - Jamaica Observer - December 9th, 2019
- CRISPR Therapeutics AG (NASDAQ:CRSP) Spiked Up 2.3% Here's Why - Lateral Line - December 9th, 2019
- Crispr Therapeutics AG (CRSP) Receives a Buy from Wells Fargo - Analyst Ratings - December 9th, 2019
- Reviewers of Chinese CRISPR Research: "Ludicrous" and "Dubious At Best" - BioSpace - December 6th, 2019
- Global CRISPR Technology Market Report 2019-2025 with Analysis of Key Companies - Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Horizon... - December 6th, 2019
- There's still a lot we don't know about China's controversial CRISPR babies, including their health status - Genetic Literacy Project - December 6th, 2019
- The Science of Product Messaging: How Unbiased Information on Pesticides, Fungicides, Herbicides, Organics, GMO and CRISPR Can Affect Consumer Buying... - December 6th, 2019
- Global and Regional CRISPR And CRISPR-Associated (Cas) Genes Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breakaway... - December 6th, 2019
- Here's Why CRISPR Therapeutics Jumped 42.2% in November - The Motley Fool - December 5th, 2019
- Chinas CRISPR babies: Read exclusive excerpts from the unseen original research - MIT Technology Review - December 5th, 2019
- Opinion: We need to know what happened to CRISPR twins Lulu and Nana - MIT Technology Review - December 5th, 2019
- Cyrus, the Broad team up to make in vivo CRISPR use safer - FierceBiotech - December 5th, 2019
- 2019: the year gene therapy came of age - FRANCE 24 - December 5th, 2019
- Here's Why Editas Medicine Jumped 45.3% in November - The Motley Fool - December 5th, 2019
- CRISPR-focused Excision BioTherapeutics Strengthens Board of Directors Appointing Veteran Pharmaceutical Executive Bill Carson, MD - GlobeNewswire - December 5th, 2019
- CRISPR Technology Market - Industry Growth, Analysis, Business Trends, Competitive Landscape, Regional Forecast to 2030 - Media Releases - CSO... - December 5th, 2019
- CRISPR and Cas Genes Market to Reach a Value of US$ 7234.5 Mn by the End of 2026 - News Description - December 5th, 2019
- Still Spinning In The Sand: CRISPR Therapeutics AG, (NASDAQ: CRSP) - Curious Coins - December 5th, 2019
- Repare Therapeutics Appoints Steve Forte as CFO and Samarth Kulkarni to Its Board of Directors - Financial Post - December 5th, 2019
- Current Trend:: CRISPR Therapeutics AG, (NASDAQ: CRSP) - Ws News Alerts - December 5th, 2019
- Genome Editing Services, World Markets to 2030: Focus on CRISPR - The Most Popular Genome Manipulation Technology Tool - PRNewswire - December 2nd, 2019
- Cyrus Biotechnology and CRISPR pioneers team up to boost gene-editing therapies - GeekWire - December 2nd, 2019
- Human Nature film review: Telling the CRISPR story with wit and verve - New Scientist - December 2nd, 2019
- Cyrus Biotechnology and the Broad Institute of MIT and Harvard Launch Multi-Target Collaboration to Develop Optimized CRISPR Gene Editing Technology -... - December 2nd, 2019
- CRISPR in Agriculture Market 2019 by Services, Application, Key Players, Size, Trends and Forecast 2025 - Downey Magazine - December 2nd, 2019
- CRISPR vs. Gene Therapy Round 1: What Investors Need to Know - The Motley Fool - November 30th, 2019
- How will CRISPR change and evolve in the future? - Drug Target Review - November 30th, 2019
- Japan and Singapore Grant CRISPR Patents to MilliporeSigma - PRNewswire - November 30th, 2019
- CRISPR Therapeutics to Present at Upcoming Investor Conferences - StreetInsider.com - November 30th, 2019
- New Research: CRISPR and Cas Genes Market Trends And Top Key Companies Profile || [Addgene Inc, AstraZeneca Plc., Bio-Rad Laboratories Inc] - Industry... - November 30th, 2019
- Growth of CRISPR Market in Global Industry: Overview, Size and Share 2019-2024 - Markets Gazette 24 - November 30th, 2019
- New Data From First Human Crispr Trials Shows Promising Results - Forbes - November 19th, 2019
- BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001 - Reuters - November 19th, 2019
- E-CRISPR could be used to rapidly detect viruses - BioNews - November 19th, 2019
- Co-creator of CRISPR lectures about future applications of genome editing technology - Daily Bruin - November 19th, 2019
- CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9... - November 19th, 2019
- BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, CRISPR Therapeutics, Slack Technologies - Nasdaq - November 19th, 2019
- CRISPR Therapeutics among healthcare gainers; Plus Therapeutics leads the losers - Seeking Alpha - November 19th, 2019
- Another step closer to curing cancer and genetic diseases: All you need to know about CRISPR-Cas9 - Firstpost - November 19th, 2019
- UC Davis leads in innovative gene editing research with NIH grants - The Aggie - November 17th, 2019
- Oppenheimer Weighs in on Crispr Therapeutics AG's Q1 2020 Earnings (NASDAQ:CRSP) - DFS Caller - November 17th, 2019
- US cancer scientists on the verge of gene editing breakthrough to treat cancer - The National - November 17th, 2019
- Youve heard of CRISPR, now meet its newer, savvier cousin CRISPR Prime - TechCrunch - November 15th, 2019
- CRISPR's unwanted anniversary - Science Magazine - November 15th, 2019
- CRISPR Could Stop Replication Of Viruses That Cause Illness, Researchers Say : Shots - Health News - NPR - November 15th, 2019
- AMD, Amarin and Crispr are three stocks to watch for potentially higher prices - MarketWatch - November 15th, 2019
- The Crispr-Cas9 patent tussle continues: The case of UC Berkeley at the EPO - Lexology - November 15th, 2019
- Science Behind the Scenes: Multiplexed CRISPR and sgRNA Arrays with the Howard Salis Lab | PLOS Synthetic Biology Community - PLoS Blogs - November 15th, 2019
- CRISPR and Cas Genes Market Estimated to Rise at a Lucrative CAGR of 20.1% During 2018-2026 - TheFinanceTime - November 15th, 2019
- CRISPR Used to Silence Crucial Hepatitis B Gene - Medscape - November 13th, 2019
- Modified CRISPR gene editing tool could improve therapies - Drug Target Review - November 13th, 2019
- Global Plant Breeding and CRISPR Plants Market is Expected to Reach USD 21.2 Million by 2025 : Fior Markets - GlobeNewswire - November 13th, 2019
- AI and gene-editing pioneers to discuss ethics - Stanford University News - November 13th, 2019
- CRISPR: the movie - Nature.com - November 12th, 2019
- Editas Medicine Announces Third Quarter 2019 Results and Update - GlobeNewswire - November 12th, 2019
- Q&A: Everything You Need to Know About the Future of CRISPR-Cas9 - Philadelphia magazine - November 11th, 2019
- Technology Networks Explores the CRISPR Revolution: An Interview With Professor Glenn Cohen, World-leading Expert on Bioethics - Technology Networks - November 11th, 2019
- As CRISPR horizons cloud, a startup focuses on the next big thing with powerhouse potential the RNA editing platform - Endpoints News - November 11th, 2019
- Doctors try CRISPR gene editing for cancer, a 1st in the US - NBCNews.com - November 8th, 2019
- A Highly Precise Cas9 Enzyme, SaCas9-HF, Is Added to the CRISPR Toolbox - Technology Networks - November 8th, 2019
- Everything You Need to Know About Superstar CRISPR Prime Editing - Singularity Hub - November 8th, 2019
- Here's Why Crispr Therapeutics Gained 22.8% in October - Motley Fool - November 8th, 2019
- CRISPR Therapeutics AG ($CRSP): Caution Is Advised (2019-11-08) - WCX19 - November 8th, 2019
- Could CRISPR Technology Rise As A Hero In The Era Of Antibiotic Resistance? - Kaiser Health News - October 30th, 2019